Century Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
IPSC$1.68-7.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · Year Ended · · Year Ended · | |||||||
| · · December 31, 2023 · · December 31, 2022 · | |||||||
| · · · | |||||||
| Cash flows from operating activities · · | |||||||
| Net loss | | $(136,673) | | $(130,932) | | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | ||
| Depreciation | | 13,044 | | 8,440 | | ||
| Amortization of deferred financing cost | | | 94 | | | 299 | |
| Non-cash operating lease expense | | | (1,196) | | | 1,631 | |
| Stock based compensation | | 14,622 | | 10,669 | | ||
| Impairment | | | 16,365 | | | — | |
| Amortization/accretion of investments | | | (3,984) | | | — | |
| Change in operating assets and liabilities: | | | | | | ||
| Escrow deposit | | 220 | | 502 | | ||
| Prepaid expenses and other assets | | 667 | | 1,028 | | ||
| Operating lease liability | | | 13,819 | | | 5,258 | |
| Deferred revenue | | | (2,235) | | | 117,988 | |
| Accounts payable | | (2,361) | | (4,788) | | ||
| Accrued expenses and other liabilities | | (730) | | 3,957 | | ||
| Net cash (used in) provided by operating activities | | (88,348) | | 14,052 | | ||
| | | | | | | | |
| Cash flows from investing activities | | | | ||||
| Acquisition of property and equipment | | (13,736) | | (30,604) | | ||
| Acquisition of fixed maturity securities, available for sale | | (209,034) | | (254,000) | | ||
| Sale of fixed maturity securities, available for sale | | 283,902 | | 271,476 | | ||
| Net cash provided by (used in) investing activities | | 61,132 | | (13,128) | | ||
| | | | | | | | |
| Cash flows from financing activities | | | | ||||
| | | | | | | | |
| Proceeds from issuance of common stock and ESPP | | | 516 | | | 345 | |
| Payments on long term debt | | | (10,241) | | | — | |
| Proceeds from issuance of shares to collaboration partner | | | — | | | 26,813 | |
| Net cash (used in) provided by financing activities | | (9,725) | | 27,158 | | ||
| | | | | | | | |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | | (36,941) | | 28,082 | | ||
| | | | | | | | |
| Cash, cash equivalents and restricted cash, beginning of period | | 86,244 | | 58,162 | | ||
| | | | | | | | |
| Cash, cash equivalents and restricted cash, end of period | | $49,303 | | $86,244 | | ||
| | | | | | | | |
| Supplemental disclosure of cash and non-cash operating activities: | | | | | | | |
| Cash paid for interest | | $586 | | $1,097 | | ||
| Cash paid for income tax | | $2,521 | | $— | | ||
| | | | | | | | |
| Supplemental disclosure of non-cash investing and financing activities: | | | | | |||
| Purchase of property and equipment, accrued and unpaid | | $352 | | $2,654 | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.